Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

CSTC1 for Diabetic Foot Ulcers Phase II Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Charsire Biotechnology Corp.
Information provided by (Responsible Party):
Charsire Biotechnology Corp. Identifier:
First received: March 12, 2013
Last updated: February 14, 2017
Last verified: February 2017
The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with diabetic foot ulcers.

Condition Intervention Phase
Diabetic Foot Ulcer
Diabetes Mellitus
Drug: CSTC1
Drug: CSTC1 Matched vehicle
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Randomized,Double-Blind,Vehicle-controlled,Parallel,Phase II Study to Evaluate Efficacy and Safety of CSTC1 in Patient With Diabetic Foot Ulcers

Resource links provided by NLM:

Further study details as provided by Charsire Biotechnology Corp.:

Primary Outcome Measures:
  • Incidence of complete ulcer closure during up to 12 weeks of treatment period [ Time Frame: 12 weeks ]
    Complete ulcer closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart.

Secondary Outcome Measures:
  • The ulcer closure time [ Time Frame: 12 weeks ]
    Defined as the time to complete ulcer closure

  • The half ulcer closure time (CT50) [ Time Frame: 12 weeks ]
    Defined as the time to half ulcer closure

  • The ulcer closure rate [ Time Frame: Weeks 1, 2, 3, 4, 6, 8, 10, 12 ]
    The proportion of ulcer closure at each post-treatment visit

  • Change from baseline in ulcer size [ Time Frame: Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12 ]
    The ulcer size at each post-treatment visit minus the ulcer size at baseline

  • Percentage change in ulcer size for each post-treatment visit [ Time Frame: Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12 ]
    Calculated as (Ulcer size at post treatment visit - Ulcer size at baseline)/(Ulcer size at baseline)

Other Outcome Measures:
  • Adverse event incidence [ Time Frame: Weeks 1, 2, 3, 4, 6, 8, 10, 12 ]
  • Change in physical examination results [ Time Frame: Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12 ]
  • Net change from baseline in laboratory test results [ Time Frame: Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12 ]
  • Net change from baseline in vital signs [ Time Frame: Baseline, weeks 1, 2, 3, 4, 6, 8, 10, 12 ]

Estimated Enrollment: 100
Study Start Date: March 2013
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: CSTC1
CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily
Drug: CSTC1
vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
Placebo Comparator: CSTC1 Matched vehicle
Matched vehicle, topical, two times daily
Drug: CSTC1 Matched vehicle


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • With either gender aged at least 20 years old;
  • With a diabetic ulcer (which is defined as the target ulcer) on the foot and not healing for at least 2 weeks;
  • The target ulcer is classified as grade 1 or 2 ulcer according to modified Wagner system;
  • The target ulcer should show "infection control" at investigator's discretion;
  • Subject should be free of any necrosis or infection in soft and bone tissue;
  • Subject has signed the written informed consent form

Exclusion Criteria:

  • With active osteomyelitis;
  • With target ulcer size decreased by at least 50% after at least 2 weeks of standard-of-care-only period or any other recorded regular therapy before Randomization visit;
  • With poor nutritional status (albumin < 3g/dl), poor diabetic control (HbA1c > 12%), anemia (hemoglobin<10 g/dL), a leukocyte counts < 1,000/mm3, abnormal liver function (AST, ALT>3 x upper limit of normal range);
  • Requiring treatment with corticosteroids, immunosuppressive or chemotherapeutic agents;
  • Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;
  • Receiving revascularization surgery performed <8 weeks before entry in the study;
  • With known or suspected hypersensitivity to any ingredients of study product and vehicle;
  • With coronary heart disease with myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior to study;
  • Pregnant or lactating or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period;
  • Enrollment in any investigational drug trial within 4 weeks before entering this study;
  • With any uncontrolled illness judged by the investigator that entering the trial may be detrimental to the subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01813305

Contact: Shr-Wei Chen, MS 886-2-2365-0660 ext 301

Kaohsiung Medical University Chung-Ho Memorial Hospital Recruiting
Kaohsiung, Taiwan
Contact: Su-Shin Lee, MD    886-7-3208176   
Sponsors and Collaborators
Charsire Biotechnology Corp.
Principal Investigator: Su-Shin Lee, MD Kaohsiung Medical University Chung-Ho Memorial Hospital
  More Information

Responsible Party: Charsire Biotechnology Corp. Identifier: NCT01813305     History of Changes
Other Study ID Numbers: CSTC1-01
Study First Received: March 12, 2013
Last Updated: February 14, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Charsire Biotechnology Corp.:
Diabetic Foot Ulcer
Diabetes Mellitus
Standard of Care

Additional relevant MeSH terms:
Diabetic Foot
Diabetes Mellitus
Foot Ulcer
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetic Neuropathies
Foot Diseases processed this record on May 25, 2017